Persistent Hypercoagulable State in COVID-19: A Case Series of COVID-19 Associated Pulmonary Embolism

Authors

Kok Hoe Chan
Su Lin Lim
Hamid Shaaban, New York Medical CollegeFollow
Gunwant Guron, New York Medical College
Jihad Slim, New York Medical CollegeFollow

Author Type(s)

Faculty

Journal Title

Journal of Global Infectious Diseases

First Page

38

Last Page

41

Document Type

Article

Publication Date

1-29-2021

Department

Medicine

Abstract

Coronavirus disease 2019 (COVID-19) has swept through the world with millions of cases and hundreds of thousands of deaths. COVID-19-associated coagulopathy has been recognized as the major cause of morbidity and mortality. To the best of our knowledge, a majority of the cases of coagulopathy have been reported in patients with moderate-to-severe COVID-19 and limited to observations during the recovery/postcytokine storm state. Herein, we report a case series of two patients with COVID-19 who developed pulmonary embolism in the late phase of the disease. This raised the hypothesis that the risk of hypercoagulability in patients with COVID-19 can persist until the recovery phase, which would warrant a follow-up with D-dimer and fibrinogen trending, as well as postdischarge thromboprophylaxis for at least 2 weeks during the recovery phase.

Recommended Citation

Chan, K., Lim, S., Shaaban, H., Guron, G., & Slim, J. (2021). Persistent Hypercoagulable State in COVID-19: A Case Series of COVID-19 Associated Pulmonary Embolism. Journal of Global Infectious Diseases, 13 (1), 38-41. https://doi.org/10.4103/jgid.jgid_180_20